FDA, FTC take aim at abuse of restricted drug programs


Last year, generic drugmakers filed 150 complaints with the Food and Drug Administration that branded drug manufacturers were misusing the agency’s regulations to block them from offering cheaper alternatives for some useful but potentially dangerous drugs.

In the wake of those complaints, the FDA, with input from the Federal Trade Commission,